The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
Bristol-Myers Squibb said Thursday said it has voluntarily withdrawn its FDA application seeking approval for a drug combination to treat advanced lung cancer.
The New York-based pharmaceutical giant said it pulled its applications for a combination of its immunotherapy drugs Opdivo and Yervoy after recent discussions with the Food and Drug Administration.
Bristol, which announced a planned $74 billion acquisition of cancer drug maker Celgene earlier this month, is still pursuing approval for the combination for use by lung cancer patients with a different biomarker. Such usage is being tested in a separate part of the study.
Sales of Bristol's blockbuster drug Opdivo, which boosts the immune system to attack cancer, has fallen behind its leading competitor, Merck's Keytruda.
In two highly anticipated clinical trials presented in April, Keytruda edged out Opdivo in reducing the risk of death from advanced lung cancer when combined with chemotherapy. Keytruda's sales surpassed Opdivo's in the second quarter of last year and widened the gap even more in the third quarter.
Earlier this month, some analysts and investors suggested that one reason Bristol may have launched its bid for Celgene — the biggest pharmaceutical deal ever — was over concerns about Opdivo's ability to compete in the all-important lung cancer market.
The announcement came as the company posted better-than-expected fourth-quarter earnings, and forecast 2019 earnings roughly in line with Wall Street expectations.
The company reported earnings of 94 cents per share, 9 cents above estimates. Revenue of $5.97 billion was in line with analyst estimates.
Bristol forecast adjusted earnings of $4.10 to $4.20 per share, excluding any impact from the Celgene deal.
Its stock was slightly higher Thursday morning.
—Reuters contributed to this report.